# A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

> **NCT07275840** · PHASE2 · RECRUITING · sponsor: **Innovent Biologics Technology Limited (Shanghai R&D Center)** · enrollment: 800 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** IBI302 8mg dose

## Key facts

- **NCT ID:** NCT07275840
- **Lead sponsor:** Innovent Biologics Technology Limited (Shanghai R&D Center)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07275840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07275840, "A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07275840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*